Epoxide Hydrolases

Announcement

You can now add alternative names! Click here to add other names that you've published under.

"Epoxide Hydrolases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Enzymes that catalyze reversibly the formation of an epoxide or arene oxide from a glycol or aromatic diol, respectively.

Descriptor ID	D004851
MeSH Number(s)	D08.811.277.340
Concept/Terms	Epoxide Hydrolases Epoxide Hydrolases Hydrolases, Epoxide Epoxide Hydratases Hydratases, Epoxide Epoxide Hydrases Hydrases, Epoxide Microsomal Epoxide Hydrolase Microsomal Epoxide Hydrolase Epoxide Hydrolase, Microsomal Hydrolase, Microsomal Epoxide Styrene Epoxide Hydrolase Styrene Epoxide Hydrolase Epoxide Hydrolase, Styrene Hydrolase, Styrene Epoxide 9,10-Epoxypalmitic Acid Hydrase 9,10-Epoxypalmitic Acid Hydrase 9,10 Epoxypalmitic Acid Hydrase Acid Hydrase, 9,10-Epoxypalmitic Hydrase, 9,10-Epoxypalmitic Acid

Below are MeSH descriptors whose meaning is more general than "Epoxide Hydrolases".

Chemicals and Drugs [D]
Enzymes and Coenzymes [D08]
Enzymes [D08.811]
Hydrolases [D08.811.277]
Epoxide Hydrolases [D08.811.277.340]

Below are MeSH descriptors whose meaning is related to "Epoxide Hydrolases".

Below are MeSH descriptors whose meaning is more specific than "Epoxide Hydrolases".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Epoxide Hydrolases" by people in UAMS Profiles by year, and whether "Epoxide Hydrolases" was a major or minor topic of these publications.

To see the data from this visualization as text, click here.

Below are the most recent publications written about "Epoxide Hydrolases" by people in Profiles over the past ten years.

Imig JD, Cervenka L, Neckar J. Epoxylipids and soluble epoxide hydrolase in heart diseases. Biochem Pharmacol. 2022 01; 195:114866.

View in: PubMed
Obeng S, Hiranita T, Le?n F, McMahon LR, McCurdy CR. Novel Approaches, Drug Candidates, and Targets in Pain Drug Discovery. J Med Chem. 2021 05 27; 64(10):6523-6548.

View in: PubMed
Grapov D, Fiehn O, Campbell C, Chandler CJ, Burnett DJ, Souza EC, Casazza GA, Keim NL, Hunter GR, Fernandez JR, Garvey WT, Hoppel CL, Harper ME, Newman JW, Adams SH. Impact of a weight loss and fitness intervention on exercise-associated plasma oxylipin patterns in obese, insulin-resistant, sedentary women. Physiol Rep. 2020 09; 8(17):e14547.

View in: PubMed
Stavniichuk A, Hye Khan MA, Yeboah MM, Chesnik MA, Jankiewicz WK, Hartmann M, Bl?cher R, Kircher T, Savchuk O, Proschak E, Imig JD. Dual soluble epoxide hydrolase inhibitor/PPAR-? agonist attenuates renal fibrosis. Prostaglandins Other Lipid Mediat. 2020 10; 150:106472.

View in: PubMed
Imig JD, Jankiewicz WK, Khan AH. Epoxy Fatty Acids: From Salt Regulation to Kidney and Cardiovascular Therapeutics: 2019 Lewis K. Dahl Memorial Lecture. Hypertension. 2020 07; 76(1):3-15.

View in: PubMed
Cert?kov? Ch?bov? V, Kujal P, Vanourkov? Z, ?karoupkov? P, Sadowski J, Kompanowska-Jezierska E, Tesar V, Hammock B, Imig J, Maxov? H, Cervenka L, Vaneckov? I. Addition of Endothelin A-Receptor Blockade Spoils the Beneficial Effect of Combined Renin-Angiotensin and Soluble Epoxide Hydrolase Inhibition: Studies on the Course of Chronic Kidney Disease in 5/6 Nephrectomized Ren-2 Transgenic Hypertensive Rats. Kidney Blood Press Res. 2019; 44(6):1493-1505.

View in: PubMed
Hye Khan MA, Schmidt J, Stavniichuk A, Imig JD, Merk D. A dual farnesoid X receptor/soluble epoxide hydrolase modulator treats non-alcoholic steatohepatitis in mice. Biochem Pharmacol. 2019 08; 166:212-221.

View in: PubMed
Imig JD. Epigenetic soluble epoxide hydrolase regulation causes endothelial dysfunction. Acta Physiol (Oxf). 2019 01; 225(1):e13203.

View in: PubMed
Hye Khan MA, Kolb L, Skibba M, Hartmann M, Bl?cher R, Proschak E, Imig JD. A novel dual PPAR-? agonist/sEH inhibitor treats diabetic complications in a rat model of type 2 diabetes. Diabetologia. 2018 10; 61(10):2235-2246.

View in: PubMed
Cert?kov? Ch?bov? V, Kujal P, ?karoupkov? P, Varnourkov? Z, Vackov? ?, Huskov? Z, Kikerlov? S, Sadowski J, Kompanowska-Jezierska E, Baranowska I, Hwang SH, Hammock BD, Imig JD, Tesar V, Cervenka L. Combined Inhibition of Soluble Epoxide Hydrolase and Renin-Angiotensin System Exhibits Superior Renoprotection to Renin-Angiotensin System Blockade in 5/6 Nephrectomized Ren-2 Transgenic Hypertensive Rats with Established Chronic Kidney Disease. Kidney Blood Press Res. 2018; 43(2):329-349.

View in: PubMed
Bettaieb A, Koike S, Hsu MF, Ito Y, Chahed S, Bachaalany S, Gruzdev A, Calvo-Rubio M, Lee KSS, Inceoglu B, Imig JD, Villalba JM, Zeldin DC, Hammock BD, Haj FG. Soluble epoxide hydrolase in podocytes is a significant contributor to renal function under hyperglycemia. Biochim Biophys Acta Gen Subj. 2017 Nov; 1861(11 Pt A):2758-2765.

View in: PubMed
Hye Khan MA, Hwang SH, Sharma A, Corbett JA, Hammock BD, Imig JD. A dual COX-2/sEH inhibitor improves the metabolic profile and reduces kidney injury in Zucker diabetic fatty rat. Prostaglandins Other Lipid Mediat. 2016 09; 125:40-7.

View in: PubMed
Dunstan SJ, Tram TT, Thwaites GE, Chau TT, Phu NH, Hien TT, Farrar JJ, Wolbers M, Mai NT. LTA4H genotype is associated with susceptibility to bacterial meningitis but is not a critical determinant of outcome. PLoS One. 2015; 10(3):e0118789.

View in: PubMed
Sporkov? A, J?chov? S, Huskov? Z, Kopkan L, Nishiyama A, Hwang SH, Hammock BD, Imig JD, Kompanowska-Jezierska E, Sadowski J, Kramer HJ, Cervenka L. Different mechanisms of acute versus long-term antihypertensive effects of soluble epoxide hydrolase inhibition: studies in Cyp1a1-Ren-2 transgenic rats. Clin Exp Pharmacol Physiol. 2014 Dec; 41(12):1003-13.

View in: PubMed
Kim J, Yoon SP, Toews ML, Imig JD, Hwang SH, Hammock BD, Padanilam BJ. Pharmacological inhibition of soluble epoxide hydrolase prevents renal interstitial fibrogenesis in obstructive nephropathy. Am J Physiol Renal Physiol. 2015 Jan 15; 308(2):F131-9.

View in: PubMed
Kim J, Imig JD, Yang J, Hammock BD, Padanilam BJ. Inhibition of soluble epoxide hydrolase prevents renal interstitial fibrosis and inflammation. Am J Physiol Renal Physiol. 2014 Oct 15; 307(8):F971-80.

View in: PubMed
Falck JR, Koduru SR, Mohapatra S, Manne R, Atcha KR, Atcha R, Manthati VL, Capdevila JH, Christian S, Imig JD, Campbell WB. 14,15-Epoxyeicosa-5,8,11-trienoic Acid (14,15-EET) surrogates: carboxylate modifications. J Med Chem. 2014 Aug 28; 57(16):6965-72.

View in: PubMed
Kujal P, Cert?kov? Ch?bov? V, ?karoupkov? P, Huskov? Z, Vernerov? Z, Kramer HJ, Walkowska A, Kompanowska-Jezierska E, Sadowski J, Kitada K, Nishiyama A, Hwang SH, Hammock BD, Imig JD, Cervenka L. Inhibition of soluble epoxide hydrolase is renoprotective in 5/6 nephrectomized Ren-2 transgenic hypertensive rats. Clin Exp Pharmacol Physiol. 2014 Mar; 41(3):227-37.

View in: PubMed
Stiborov? M, Moserov? M, Cern? V, Indra R, Drac?nsk? M, ?ulc M, Henderson CJ, Wolf CR, Schmeiser HH, Phillips DH, Frei E, Arlt VM. Cytochrome b5 and epoxide hydrolase contribute to benzo[a]pyrene-DNA adduct formation catalyzed by cytochrome P450 1A1 under low NADPH:P450 oxidoreductase conditions. Toxicology. 2014 Apr 06; 318:1-12.

View in: PubMed